Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.226
-0.016 (-6.66%)
Dec 5, 2025, 4:00 PM EST - Market closed
Theriva Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 6.22 | 6.7 | 7.78 | 7.57 | 6.47 | 5.03 | |
| Research & Development | 10.36 | 12.03 | 14.31 | 11.72 | 7.8 | 5.13 | |
| Operating Expenses | 16.58 | 18.73 | 22.09 | 19.29 | 14.27 | 10.16 | |
| Operating Income | -16.58 | -18.73 | -22.09 | -19.29 | -14.27 | -10.16 | |
| Interest & Investment Income | 0.35 | 0.7 | 1.44 | 0.51 | 0.01 | 0.04 | |
| Currency Exchange Gain (Loss) | 0.03 | -0 | 0 | -0.04 | - | - | |
| EBT Excluding Unusual Items | -16.2 | -18.04 | -20.65 | -18.82 | -14.27 | -10.12 | |
| Merger & Restructuring Charges | - | - | - | -0.2 | - | - | |
| Impairment of Goodwill | - | -5.59 | - | - | - | - | |
| Other Unusual Items | -9.99 | -0.7 | 0.66 | -2.09 | - | - | |
| Pretax Income | -26.19 | -25.65 | -19.99 | -21.11 | -14.27 | -10.12 | |
| Income Tax Expense | - | - | -1.64 | -1.43 | - | - | |
| Earnings From Continuing Operations | -26.19 | -25.65 | -18.35 | -19.69 | -14.27 | -10.12 | |
| Minority Interest in Earnings | - | - | - | - | 0 | 0.07 | |
| Net Income | -26.19 | -25.65 | -18.35 | -19.69 | -14.27 | -10.04 | |
| Preferred Dividends & Other Adjustments | - | - | - | 0.34 | 8.92 | 2.51 | |
| Net Income to Common | -26.19 | -25.65 | -18.35 | -20.03 | -23.19 | -12.56 | |
| Shares Outstanding (Basic) | 6 | 1 | 1 | 1 | 0 | 0 | |
| Shares Outstanding (Diluted) | 6 | 1 | 1 | 1 | 0 | 0 | |
| Shares Change (YoY) | 572.67% | 109.24% | 5.09% | 25.76% | 541.07% | 15.65% | |
| EPS (Basic) | -4.74 | -19.03 | -28.48 | -32.66 | -47.57 | -165.13 | |
| EPS (Diluted) | -4.74 | -19.03 | -28.48 | -32.66 | -47.57 | -165.13 | |
| Free Cash Flow | -18.51 | -16.94 | -19.2 | -19.2 | -12.9 | -12.18 | |
| Free Cash Flow Per Share | -3.35 | -12.56 | -29.80 | -31.31 | -26.47 | -160.13 | |
| EBITDA | -16.47 | -18.59 | -21.96 | -19.21 | -14.19 | -9.96 | |
| D&A For EBITDA | 0.11 | 0.14 | 0.14 | 0.09 | 0.09 | 0.2 | |
| EBIT | -16.58 | -18.73 | -22.09 | -19.29 | -14.27 | -10.16 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.